Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (161-170 of 703) with videos related to

Pageof 71
Sort By:
Cancer|June 28, 2012
Number of primary melanomas is an independent predictor of survival in patients with metastatic melanomaRajmohan Murali, Philip T Brown, Richard F Kefford, et al.
BMC Nephrology|September 7, 2020
Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series reportSebastian Hultin, Kazi Nahar, Alexander M Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2021
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanomaF Dimitriou, S N Lo, A C Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2019
Reply to A. Shinde et alHarriet M Kluger, Kim A Margolin, Michael A Davies, et al.
Pathology|March 6, 2022
Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanomaAndrew J Colebatch, Elizabeth C Paver, Ismael A Vergara, et al.
BMC Cancer|September 11, 2021
Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviewsAnn Livingstone, Kathy Dempsey, Martin R Stockler, et al.
Pathology|December 1, 2018
Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 casesTristan J Dodds, James S Wilmott, Louise A Jackett, et al.
BMC Cancer|October 22, 2025
Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1-5 extracranial melanoma oligometastases (AXIOM)Angela M Hong, Tim Wang, Matteo S Carlino, et al.
Clinical Endocrinology|July 14, 2025
Testicular Function After Immune-Checkpoint Inhibitors TreatmentAndrea Boutros, Amanda Idan, Sue Sleiman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Incidence of new primary melanomas after diagnosis of stage III and IV melanomaLisa Zimmer, Lauren E Haydu, Alexander M Menzies, et al.
Pageof 71

Showing results (161-170 of 703) with videos related to

Sort By:
Pageof 71
Cancer|June 28, 2012
Number of primary melanomas is an independent predictor of survival in patients with metastatic melanomaRajmohan Murali, Philip T Brown, Richard F Kefford, et al.
BMC Nephrology|September 7, 2020
Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series reportSebastian Hultin, Kazi Nahar, Alexander M Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2021
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanomaF Dimitriou, S N Lo, A C Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2019
Reply to A. Shinde et alHarriet M Kluger, Kim A Margolin, Michael A Davies, et al.
Pathology|March 6, 2022
Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanomaAndrew J Colebatch, Elizabeth C Paver, Ismael A Vergara, et al.
BMC Cancer|September 11, 2021
Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviewsAnn Livingstone, Kathy Dempsey, Martin R Stockler, et al.
Pathology|December 1, 2018
Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 casesTristan J Dodds, James S Wilmott, Louise A Jackett, et al.
BMC Cancer|October 22, 2025
Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1-5 extracranial melanoma oligometastases (AXIOM)Angela M Hong, Tim Wang, Matteo S Carlino, et al.
Clinical Endocrinology|July 14, 2025
Testicular Function After Immune-Checkpoint Inhibitors TreatmentAndrea Boutros, Amanda Idan, Sue Sleiman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Incidence of new primary melanomas after diagnosis of stage III and IV melanomaLisa Zimmer, Lauren E Haydu, Alexander M Menzies, et al.
Pageof 71